4.8 Article

viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia

Journal

NATURE BIOTECHNOLOGY
Volume 31, Issue 6, Pages 545-+

Publisher

NATURE PORTFOLIO
DOI: 10.1038/nbt.2594

Keywords

-

Funding

  1. National Science Foundation CAREER award [MCB-1149728]
  2. National Institutes of Health Roadmap Initiative
  3. NIH Director's New Innovator Award Program [1-DP2-OD002414-01]
  4. National Centers for Biomedical Computing [1U54CA121852-01A1]
  5. Alex's Lemonade Fund Young Investigator Award
  6. St. Baldrick's Foundation Scholar Award
  7. Damon Runyon Cancer Research Foundation Fellowship [DRG-2017-09]
  8. Rachford and Carlota A. Harris Endowed Professorship
  9. European Commission HEALTH [2010.1.2-1]
  10. Bill and Melinda Gates Foundation [GF12141-137101]
  11. [U19 AI057229]
  12. [P01 CA034233]
  13. [HHSN272200700038C]
  14. [1R01CA130826]
  15. [CIRM DR1-01477]
  16. [RB2-01592]
  17. [NCI RFA CA 09-011]
  18. [NHLBIHV-10-05(2)]
  19. Div Of Molecular and Cellular Bioscience
  20. Direct For Biological Sciences [1149728] Funding Source: National Science Foundation

Ask authors/readers for more resources

New high-dimensional, single-cell technologies offer unprecedented resolution in the analysis of heterogeneous tissues. However, because these technologies can measure dozens of parameters simultaneously in individual cells, data interpretation can be challenging. Here we present viSNE, a tool that allows one to map high-dimensional cytometry data onto two dimensions, yet conserve the high-dimensional structure of the data. viSNE plots individual cells in a visual similar to a scatter plot, while using all pairwise distances in high dimension to determine each cell's location in the plot. We integrated mass cytometry with viSNE to map healthy and cancerous bone marrow samples. Healthy bone marrow automatically maps into a consistent shape, whereas leukemia samples map into malformed shapes that are distinct from healthy bone marrow and from each other. We also use viSNE and mass cytometry to compare leukemia diagnosis and relapse samples, and to identify a rare leukemia population reminiscent of minimal residual disease. viSNE can be applied to any multi-dimensional single-cell technology.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available